1. Pink Sheet
  2. >>Geography
  3. >>Europe

Companies Get Yet More Time To Assess Nitrosamine Risk In EU

Deadline For Assessing Chemical Medicines Extended Until 31 March 2021

 
• By Vibha Sharma

After EU regulators decided that biological medicines should be reviewed for the presence of possible nitrosamine impurities – as is already required for chemical medicines – new deadlines have been agreed on to give companies enough time to comply.

Nitrosodimethylamine
Nitrosamines are classified as probable human carcinogens • Source: Shutterstock

EU regulators are giving yet more time to sponsors of medicines containing chemically synthesized active pharmaceutical ingredients to assess their products for the possible presence of cancer-causing nitrosamine impurities. They have also set a new deadline for sponsors of biological medicines to carry out similar assessments.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography